A detailed history of Mather Group, Llc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Mather Group, Llc. holds 13 shares of BGNE stock, worth $2,497. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13
Holding current value
$2,497
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

BUY
$143.93 - $224.51 $1,871 - $2,918
13 New
13 $2,000
Q1 2024

Apr 08, 2024

BUY
$141.8 - $181.47 $567 - $725
4 New
4 $0

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $19.9B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Mather Group, Llc. Portfolio

Follow Mather Group, Llc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mather Group, Llc., based on Form 13F filings with the SEC.

News

Stay updated on Mather Group, Llc. with notifications on news.